Zenith Drugs Key Ratios
NSE: ZENITHDRUG
₹39.85
₹-0.15
(-0.38%)
As on 03-Sep-2026 15:50IST
Market cap
₹68 Cr
Revenue (TTM)
₹133 Cr
P/E Ratio
17.3
P/B Ratio
1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 1.29 | 13.30 | -- |
| EBIT | -- | -- | -29.00 | 24.83 | -- |
| Net Profit | -- | -- | -24.92 | 30.62 | -- |
| EPS | -- | -- | -24.92 | 15.97 | -- |
| Book Value | -- | -- | 11.51 | 55.75 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 8.89 | -- | 8.15 | 11.63 | 6.90 |
| Net Margin
| 5.53 | -- | 5.27 | 7.11 | 4.22 |
| Return on equity
| 22.22 | -- | 10.88 | 23.86 | 31.92 |
| Return on Capital
| 21.09 | -- | 12.96 | 25.20 | 25.12 |
| Return on Assets
| 6.35 | -- | 4.85 | 8.25 | 5.97 |
| Debt to Equity (x)
| -- | -- | 0.70 | 0.38 | 1.43 |
Profitability
ROCE
12.96
Lower than Peers by 3.50
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
12.96
|
25.20
|
25.12
|
23.87
|
24.25
|
|
Peer Median
|
16.46
|
15.49
|
17.37
|
17.62
|
--
|
ROE
10.88
Lower than Peers by 2.99
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
10.88
|
23.86
|
31.92
|
28.57
|
31.82
|
|
Peer Median
|
13.87
|
14.72
|
15.70
|
18.36
|
--
|
ROA
4.85
Lower than Peers by 3.19
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
4.85
|
8.25
|
5.97
|
5.70
|
6.59
|
|
Peer Median
|
8.04
|
7.19
|
9.43
|
9.43
|
--
|
EBIT Margin
8.15
Lower than Peers by 1.90
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
8.15
|
11.63
|
6.90
|
6.09
|
8.14
|
|
Peer Median
|
10.05
|
10.28
|
13.90
|
17.27
|
--
|
Net Margin
5.27
Lower than Peers by 3.84
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
5.27
|
7.11
|
4.22
|
3.47
|
4.17
|
|
Peer Median
|
9.11
|
6.78
|
10.91
|
12.99
|
--
|
Cash Profit Margin
6.67
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
6.67
|
7.21
|
4.83
|
4.48
|
5.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
1.29
Lower than Peers by 5.87
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
1.29
|
14.93
|
24.95
|
24.87
|
--
|
|
Peer Median
|
7.17
|
10.56
|
12.63
|
15.47
|
--
|
EBIT Growth
-29.00
Lower than Peers by 41.05
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
-29.00
|
93.58
|
41.51
|
-6.55
|
--
|
|
Peer Median
|
12.05
|
6.17
|
-2.90
|
51.73
|
--
|
Net Profit Growth
-24.92
Lower than Peers by 47.06
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
-24.92
|
95.38
|
51.92
|
4.77
|
--
|
|
Peer Median
|
22.15
|
27.97
|
-14.10
|
44.15
|
--
|
EPS Growth
-24.92
Lower than Peers by 33.72
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
-24.92
|
36.72
|
51.92
|
4.77
|
--
|
|
Peer Median
|
8.80
|
--
|
-3.68
|
38.52
|
--
|
Book Value Growth
11.51
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
11.51
|
250.88
|
37.98
|
33.34
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.70
Higher than Peers by 0.67
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
0.70
|
0.38
|
1.43
|
1.31
|
1.61
|
|
Peer Median
|
0.03
|
0.05
|
0.14
|
0.23
|
--
|
Short term debt to equity ratio
0.44
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
0.44
|
0.23
|
0.89
|
0.72
|
0.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.45
Lower than Peers by 0.75
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
1.45
|
1.76
|
1.17
|
1.18
|
1.22
|
|
Peer Median
|
2.20
|
1.93
|
1.82
|
1.75
|
--
|
Quick Ratio
0.95
Lower than Peers by 0.76
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
0.95
|
1.36
|
0.84
|
0.91
|
0.99
|
|
Peer Median
|
1.72
|
1.59
|
1.30
|
1.04
|
--
|
Interest Coverage
3.34
Lower than Peers by 8.95
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
3.34
|
5.43
|
3.68
|
3.06
|
4.08
|
|
Peer Median
|
12.28
|
12.45
|
16.98
|
15.07
|
--
|
Operating Efficiency
Debtors to sales
45.44
Higher than Peers by 19.21
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
45.44
|
51.20
|
43.06
|
34.99
|
31.86
|
|
Peer Median
|
26.23
|
23.97
|
24.57
|
20.26
|
--
|
Asset Turnover
1.03
Higher than Peers by 0.29
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
1.03
|
1.30
|
1.57
|
1.80
|
1.74
|
|
Peer Median
|
0.74
|
0.88
|
0.82
|
0.79
|
--
|
Receivable days
153.74
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
153.74
|
141.66
|
115.89
|
99.59
|
105.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
78.54
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
78.54
|
60.00
|
50.99
|
34.05
|
30.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
238.18
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
238.18
|
300.96
|
275.83
|
137.57
|
141.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-5.90
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
-5.90
|
-99.30
|
-108.95
|
-3.92
|
-5.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
17.17
Lower than Peers by 22.00
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
17.17
|
11.27
|
--
|
--
|
--
|
|
Peer Median
|
39.17
|
40.74
|
25.97
|
33.71
|
--
|
Price / Book Value
1.77
Lower than Peers by 1.83
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
1.77
|
1.73
|
--
|
--
|
--
|
|
Peer Median
|
3.61
|
3.87
|
2.79
|
4.36
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
--
|
0.80
|
--
|
--
|
--
|
|
Peer Median
|
0.19
|
0.20
|
0.65
|
0.28
|
--
|
EV/EBITDA
10.42
Lower than Peers by 18.37
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
10.42
|
6.41
|
2.45
|
1.82
|
1.92
|
|
Peer Median
|
28.79
|
25.41
|
15.07
|
23.32
|
--
|
Market Cap
123
Lower than Peers by 3,822
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Zenith Drugs
|
123
|
108
|
--
|
--
|
--
|
|
Peer Median
|
3,944
|
2,959
|
3,742
|
6,050
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
